| Assessment Status | Rapid Review Complete |
| HTA ID | 23049 |
| Drug | Chlormethine gel |
| Brand | Ledaga® |
| Indication | Chlormethine gel (Ledaga®) is indicated for the topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma (MF-type CTCL) in adult patients. |
| Assessment Process | |
| Rapid review commissioned | 31/07/2023 |
| Rapid review completed | 20/09/2023 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that chlormethine gel not be considered for reimbursement at the submitted price*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
The HSE has approved reimbursement following confidential price negotiations. July 2024
